Clinical and regulatory intelligence for Colorectal Cancer with 34 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 34
Catalysts: 0
Assets: 26

Relevant assets

Altered →

Atezolizumab →

Relevant companies

oncology pharmaceutical companies →

Pfizer →

Roche →

Takeda →

Recent signals(34)

ClinicalJuly 31, 2026

Fusobacterium nucleatum adhesins linked to colorectal cancer progression

Fusobacterium nucleatum adhesins play a significant role in colorectal cancer progression by mediating tumor growth and immune evasion.

ClinicalJuly 28, 2026

Insights into Precision Therapy for Colorectal Cancer Targeting Key Molecular Pathways

The review discusses critical signaling pathways involved in colorectal cancer, including Wnt/β-catenin and MAPK/ERK, and their role in tumorigenesis.

ClinicalJuly 25, 2026

Comparative Study of Raltitrexed and Oxaliplatin in Metastatic Colorectal Cancer

A randomized pharmacokinetic study is underway comparing biweekly and triweekly regimens of raltitrexed and oxaliplatin in metastatic colorectal cancer.

ClinicalJuly 19, 2026

Yale University Launches Pragmatic Trial for Colorectal Cancer Screening Adherence

Yale University is conducting a 4-arm pragmatic trial aimed at enhancing adherence to colorectal cancer screening through a multicomponent intervention.

ClinicalJuly 19, 2026

SEPTIN9 methylation in ctDNA predicts MRD in colorectal cancer patients post-surgery

The study evaluates SEPTIN9 methylation status in ctDNA as a biomarker for minimal residual disease in colorectal cancer.

ClinicalJuly 14, 2026

AI-Driven Insights on Gut Microbiome's Role in Colorectal Cancer Therapy

The gut microbiome significantly influences tumor development and treatment outcomes in colorectal cancer, highlighting its potential as a biomarker.

ClinicalJuly 13, 2026

Gut Microbiota's Role in Colorectal Cancer: Insights for Targeted Therapies

The review highlights how gut microbiota influences colorectal cancer through mutations and immune microenvironment alterations.

ClinicalJuly 12, 2026

Immune Profiling in dMMR/MSI-H CRC Reveals Prognostic Insights and Immunotherapeutic Potential

The study identifies significant differences in immune cell infiltration and expression of IDO1 in dMMR/MSI-H CRC based on tumor stage, suggesting varying prognostic implications.

ClinicalJuly 11, 2026

Peptostreptococcus as a potential biomarker and therapeutic target in colorectal cancer

The oral bacterium Peptostreptococcus may influence colorectal cancer progression and serves as a potential biomarker.

ClinicalJuly 11, 2026

Study on Bioelectrical Impedance Analysis in Colorectal Cancer Surgery

A study is evaluating bioelectrical impedance analysis for assessing fluid balance in colorectal cancer surgery patients.

ClinicalJuly 11, 2026

Phase I/II Trial of STAR15 Combination Therapy for Metastatic Colorectal Cancer

A Phase I/II study is underway to evaluate a combination of four experimental therapies for metastatic colorectal cancer.

ClinicalJuly 10, 2026

Surufatinib plus FOLFOX/FOLFIRI shows potential in mCRC second-line therapy

A randomized phase-II trial is assessing surufatinib combined with FOLFOX/FOLFIRI against FOLFOXIRI for mCRC.

ClinicalJuly 10, 2026

Intraoperative Fluid Exposure Affects Early Bowel Recovery in Colorectal Cancer Surgery

The study suggests that intraoperative fluid exposure may impact the time to first flatus after laparoscopic colorectal cancer surgery.

CompetitiveJuly 9, 2026

City of Hope Initiates Liquid Biopsy Study for Early Colorectal Cancer Detection

A new study is underway to develop a non-invasive liquid biopsy assay using cf-circRNAs for early detection of colorectal cancer.

ClinicalJuly 7, 2026

Study on Biomarkers for Predicting Recurrence in Colorectal Cancer Launched

A new study aims to explore biomarkers for predicting local recurrence and distant metastasis in colorectal cancer.

ClinicalJuly 6, 2026

PRX5 identified as key regulator in colorectal cancer stem cell formation

The study highlights PRX5's role in sustaining colorectal cancer stem cell identity and tumorigenicity.

ClinicalJuly 6, 2026

New Orthotopic Model Reveals CD8⁺ T Cell Dysfunction in Colorectal Cancer Immunotherapy

A novel orthotopic organoid-based model for colorectal cancer demonstrates CD8⁺ T cell dysfunction and responsiveness to anti-PD-1 therapy.

ClinicalJuly 4, 2026

Discovery of DP8α Tregs in Colorectal Cancer Reveals New Immune Suppression Mechanism

DP8α regulatory T cells are significantly enriched in colorectal cancer tumors and exhibit a suppressive phenotype.

ClinicalJuly 2, 2026

Study on mFOLFOX6+Bevacizumab+PD-1 in Local Advanced MSS CRC Initiated

A clinical trial is underway to evaluate the safety and efficacy of mFOLFOX6 combined with Bevacizumab and PD-1 monoclonal antibody in patients with local advanced pMMR/MSS colorectal cancer.

ClinicalJune 30, 2026

MBD2's Role in Silencing SFRP1 Identifies Potential CRC Therapeutic Targets

MBD2 suppresses SFRP1 expression in colorectal cancer by blocking MED19 binding to its methylated promoter.

ClinicalJune 30, 2026

Altered Immune Cell Interactions with Bacterial LPS in Colorectal Cancer Revealed

The study reveals distinct differences in immune cell interactions with bacterial lipopolysaccharide (LPS) between colorectal cancer (CRC) tumors and adjacent tissue.

CompetitiveJune 25, 2026

Cadonilimab Targets PD-1/PD-L1 Blockade-Refractory MSI-H/dMMR Colorectal Cancer

Cadonilimab, a bispecific anti-PD-1/CTLA-4 antibody, is being evaluated for advanced colorectal cancer patients who are refractory to PD-1/PD-L1 blockade.

ClinicalJune 24, 2026

ADAR1-circRAB5A-BIP axis linked to radiotherapy resistance in colorectal cancer

The study identifies the ADAR1-circRAB5A-BIP axis as a key regulator of radiotherapy resistance in colorectal cancer by balancing autophagy and apoptosis.

ClinicalJune 23, 2026

Chemoimmunotherapy Shows Promise in MSS Colorectal Cancer: Pooled Analysis Insights

Pooled analysis from MEDITREME and METIMMOX studies indicates that first-line chemoimmunotherapy may effectively treat metastatic microsatellite stable colorectal cancer.

ClinicalJune 22, 2026

SLC22A4 Variants Influence Fusobacterium nucleatum in Colorectal Cancer

Variants of the SLC22A4 transporter affect the abundance of Fusobacterium nucleatum in colorectal cancer, linking genetic factors to microbiota composition.

ClinicalJune 21, 2026

CircKPNA2 promotes colorectal cancer via RIN1-Ras pathway activation

CircKPNA2 is upregulated in colorectal cancer and activates the RIN1-Ras pathway, promoting tumor growth.

ClinicalJune 21, 2026

Novel KRAS(G12V)-targeting peptide shows potent activity against colorectal cancer cells

Peptide-1 demonstrated strong binding affinity to KRAS G12V and potent antiproliferative effects in colorectal cancer cell lines.

ClinicalJune 20, 2026

Lidocaine enhances efficacy of sorafenib and GW5074 in colorectal cancer cell lines

Lidocaine significantly enhances the antitumor effects of sorafenib and GW5074 in colorectal cancer cells, with varying responses across different cell lines.

ClinicalJune 19, 2026

Fruquintinib Study in Metastatic Colorectal Cancer Patients in Poland

A study is underway to evaluate the efficacy of fruquintinib in adults with metastatic colorectal cancer in Poland, focusing on progression-free survival and overall survival.

ClinicalJune 18, 2026

Phase III Trial of Atezolizumab with Chemotherapy for Metastatic Colorectal Cancer Initiated

The COMMIT study is evaluating the efficacy of atezolizumab in combination with chemotherapy and bevacizumab for metastatic colorectal cancer with DNA mismatch repair deficiency.

ClinicalJune 18, 2026

Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial

A clinical trial is underway to evaluate onvansertib combined with standard therapies for first-line treatment of KRAS/NRAS-mutated metastatic colorectal cancer.

ClinicalJune 17, 2026

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

The study identifies age, neoadjuvant therapy, and tumor characteristics as risk factors for second primary cancer in colorectal cancer survivors.

ClinicalJune 17, 2026

Phase II Trial Compares FOLFOX8 and mFOLFOX6 in Metastatic Colorectal Cancer

A phase II trial is underway to compare the efficacy and safety of FOLFOX8 versus mFOLFOX6 with bevacizumab or cetuximab in patients with unresectable metastatic colorectal cancer.

ClinicalJune 16, 2026

Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in mCRC

The Phase 3 BREAKWATER study showed BRAFTOVI combined with cetuximab and FOLFIRI nearly doubled median progression-free survival to 15.2 months compared to 8.3 months with the comparator.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Colorectal Cancer →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.